StockRunway.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
New York, NY -- (SBWIRE) -- 01/30/2014 -- StockRunway.com issues special report on – Dendreon Corporation (NASDAQ:DNDN), CYS Investments Inc (NYSE:CYS), XOMA Corp (NASDAQ:XOMA), Two Harbors Investment Corp (NYSE:TWO)
Dendreon Corporation (NASDAQ:DNDN) showed a volume of 2.14 million shares by the end of last trade whereas the average volume of the stock remained 5.05 million shares. The stock opened the session at $2.73 but then moved to $2.79. At that price, the stock showed a positive performance of 1.82%. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients.
Will DNDN Continue To Move Higher? Find Out Here
CYS Investments Inc (NYSE:CYS) opened the session at $7.80 and closed the session at $7.84. The stock showed a positive performance of 0.13% in previous trading session. Traded with volume of 2.10 million shares in the prior session and the average volume of the stock remained 2.80 million shares. CYS Investments, Inc. is a specialty finance company created with the objective of achieving consistent risk-adjusted investment income. The Company invests in Agency residential mortgage-backed securities (RMBS) collateralized by fixed rate single-family residential mortgage loans (typically 15, 20 or 30 years), adjustable-rate mortgage loans (ARMs), which typically have coupon rates that reset monthly,
For How Long CYS will fight for Profitability? Read This Trend Analysis report
XOMA Corp (NASDAQ:XOMA) opened the session at $7.4 and closed the session at $7.65. The stock showed a positive performance of 0.26% in previous trading session. Traded with volume of 2.10 million shares in the prior session and the average volume of the stock remained 2.47 million shares. The beta of the stock remained 2.41. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta).
Why Should Investors Buy XOMA After The Recent Gain? Just Go Here and Find Out
Two Harbors Investment Corp (NYSE:TWO) traded with volume of 2.02 million shares in the prior session and the average volume of the stock remained 4.14 million shares. The beta of the stock remained 0.47. Two Harbors Investment Corp. (Two Harbors) operates as a real estate investment trust (REIT). The Company is focused on investing in, financing and managing residential mortgage-backed securities (RMBS), residential mortgage loans,
Is TWO a Solid Investment at These Levels? Read This Report For Details
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you're new to penny stocks or a seasoned veteran, you'll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.
Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway's service today!
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.
Read Our Full Disclaimer at: http://www.stockrunway.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)